HC Wainwright Has Positive Outlook of Brainsway Q2 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for Brainsway in a research report issued to clients and investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.10 per share for the quarter, up from their previous forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.30 per share. HC Wainwright also issued estimates for Brainsway’s Q3 2026 earnings at $0.13 EPS, Q1 2027 earnings at $0.14 EPS, Q2 2027 earnings at $0.15 EPS, Q3 2027 earnings at $0.19 EPS, Q4 2027 earnings at $0.21 EPS and FY2027 earnings at $0.69 EPS.

BWAY has been the subject of several other reports. Weiss Ratings raised shares of Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a report on Friday, April 24th. Wall Street Zen cut shares of Brainsway from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Zacks Research lowered Brainsway from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $16.00.

Brainsway Stock Up 5.2%

BWAY opened at $15.89 on Wednesday. The firm has a 50-day moving average price of $14.87 and a 200-day moving average price of $12.00. Brainsway has a twelve month low of $5.01 and a twelve month high of $17.35. The company has a market capitalization of $636.20 million, a price-to-earnings ratio of 45.40 and a beta of 1.23.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The company had revenue of $15.53 million during the quarter, compared to the consensus estimate of $14.63 million.

Institutional Investors Weigh In On Brainsway

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Y.D. More Investments Ltd grew its position in Brainsway by 559.8% during the fourth quarter. Y.D. More Investments Ltd now owns 114,962 shares of the company’s stock worth $2,187,000 after buying an additional 97,537 shares in the last quarter. Zuckerman Investment Group LLC grew its position in Brainsway by 5.3% in the third quarter. Zuckerman Investment Group LLC now owns 40,000 shares of the company’s stock worth $603,000 after acquiring an additional 2,000 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in shares of Brainsway by 3.2% during the third quarter. Essex Investment Management Co. LLC now owns 310,684 shares of the company’s stock valued at $4,682,000 after purchasing an additional 9,744 shares during the period. Raymond James Financial Inc. bought a new position in shares of Brainsway in the second quarter worth approximately $85,000. Finally, Masters Capital Management LLC increased its stake in shares of Brainsway by 65.0% in the first quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock worth $21,928,000 after buying an additional 650,000 shares during the period. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.